Future Directions

Athletes may potentially benefit from pharmaceutical agents that prevent stress fractures or speed the healing process of acute and stress fractures. The value of such medications will depend on how quickly the athlete returns to competition in relation to the financial costs and possible negative side effects. As discussed, there is currently no clear evidence that any of the discussed agents either facilitate or impede human fracture healing.

The recent discoveries of several bone-forming growth factors will ensure that research continues in this field. Bone morphogenic proteins, fibroblast growth factors, transforming growth factor-13, and other growth factors may eventually play a pivotal role in both fracture prevention and treatment. Interestingly, insulin-like growth factor (IGF)-I may interact significantly with PTH as a mediator of bone formation, in part by secreting IGF-I binding proteins in osteoblast-like cells [12].

The efficacy of any pharmaceutical agents will be determined only through large, randomized clinical trials. Although disease-oriented outcome measures such as bone mass density and callous size have been used in previous trials, future research must focus on patient-oriented outcomes such as time to return to full activity and decreased pain. The trials should consist of multicenter efforts, enrolling a large number of individuals participating in a variety of sports to allow for a representative number of different fractures. Without such highlevel evidence, any definitive comment on the positive or negative effects of PTH, bisphosphonates, or NSAIDs is purely speculative.

References

[1] Hame SL, LaFemina JM, McAllister DR, etal. Fractures in the collegiate athlete. Am J Sports Med 2004;32:446-51.

[2] Adolphson P, Abbaszadegan H, Boden H, et al. Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 2000;71:195-200.

[3] van der Poest Clement E, Patka P, Vandormael K, Haarman H, et al. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 2000;15:586-93.

[4] Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res 2001;16:437-40.

[5] Li C, Mori S, Li J, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 2001;16:429-36.

[6] Burr DB. Pharmaceutical treatments that may prevent or delay the onset of stress fractures. In: Burr DB, Milgrom C, editors. Musculoskeletal fatigue and stress fractures. Boca Raton (FL): CRC Press; 2001. p. 259-70.

[7] Milgrom C, Finestone A, Novack V, et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone 2004;35:41 8-24.

[8] Stewart GW, Brunet ME, Manning M, et al. Treatment of stress fractures in athletes with intravenous pamidronate. Clin J Sport Med 2005;15:92-4.

[9] Patlas N, Golomb G, Yaffe P, et al. Transplacental effects bisphosphonates on fetal skeleton ossification and mineralization in rats. Teratology 1999;60:68-73.

[10] Geddes AD, D'Souza SM, Ebetino FH, et al. Bisphosphonates structure-activity relationships and therapeutic implications. J Bone Miner Res 1994;8:265-306.

[11] Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in rats. Toxicol Appl Pharmacol 1993;121:217-23.

[12] Skripitz R, Aspenburg P. Parathyroid hormone: a drug for orthopaedic surgery? Acta Orthop Scand 2004;75:654-62.

[13] Selye H. On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547-8.

[14] Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-8.

[15] Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 1995;10:948-55.

[16] Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.

[17] Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens PTH-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278:50259-72.

[18] Frost HM, Jee WS. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992;18:227-36.

[19] Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.

[20] Cosman F, Lindsay R. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 1998;62:475-80.

[21] Dempster DW, Cosman F, Kurland ES, et al. Effect of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.

[22] Halloran BP, Birkle DD, Harris J, et al. Regional responsiveness of the tibia to intermittent administration of parathyroid hormone as affected by skeletal unloading. J Bone Miner Res 1997;12:1068-74.

[23] Zhang L, Takahashi HE, Inoue J, et al. Effects of intermittent administration of low dose human PTH (1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles. Bone 1997;21:501-6.

[24] Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999;14:960-8.

[25] Skripitz R, Andreassen TT, Aspenberg P. Strong effect of PTH (1-34) on regenerating bone: a time sequence study in rats. Acta Orthop Scand 2000;71:619-24.

[26] Holzer G, Majeska RJ, Lundy MW, et al. Parathyroid hormone enhances fracture healing: a preliminary report. Clin Orthop 1999;366:258-63.

[27] Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 2002;17:2038-47.

[28] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;334:1434-41.

[29] Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to com pare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35.

[30] Omeroglu H, Ates Y, Akkus O, et al. Biomechanical analysis of the effects of single highdose vitamin D3 on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg 1997;116:271-4.

[31] Delgado-Martinez AD, Martinez ME, Carrascal MT, et al. Effect of 25-OH-vitamin D on fracture healing in elderly rats. J Orthop Res 1998;16:650-3.

[32] Brumbaugh PF, Speer DP, Pitt MJ. 1-alpha, 25-Dihydroxyvitamin D3 a metabolite of vitamin D that promotes bone repair. Am J Pathol 1982;106:171-9.

[33] Doetsch AM, Faber J, Lynnerup N, et al. The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcif Tissue Int 2004;75:183-8.

[34] Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.

[35] Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.

[36] Gerstenfeld L, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by nonselective and cyclooxygenase-2 (COX2) selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003;21:67.

[37] Brown KM, Saunders MM, Kirsch T, et al. Effect of COX-2 specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am 2004;86A:116-23.

[38] Allen H, Wase A, Bear W. Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand 1980; 51:595-600.

[39] Altman RD, Latta LL, Keer R, et al. Effect of nonsteroidal anti-inflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma 1995;9:392-400.

[40] Elves M, Bayley I, Raylance P. The effect of indomethacin upon experimental fractures in the rat. Acta Orthop Scand 1982;53:35-41.

[41] Hogevold H, Grogaard B, Reikeras O. Effects of short-term treatment with corticosteroids and indomethacin on bone healing. Acta Orthop Scand 1992;63:600-11.

[42] Suddmann E, Tveita T, Hald J. Lack of effect of indomethacin on ordered growth of the femur in rats. Acta Orthop Scand 1982;53:43-9.

[43] Bennell K, Brukner P. How should you treat a stress fracture? In: MacAuley D, BestT, editors. Evidence based sports medicine, volume 26. London: BMJ Books; 2002. p. 491-517.

[44] Wheeler P, Batt ME. Do non-steroidal anti-inflammatory drugs adversely affect stress fracture healing? A short review. Br J Sports Med 2005;39:65-9.

[45] Adolphson P, Abbaszadegan H, Jonsson U, et al. No effects of piroxicam on osteopenia and recovery after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg 1993;112:127-30.

[46] Bhattacharyya T, Levin R, Vrahas MS, et al. Nonsteroidal anti-inflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 2005;53(3):364-7.

[47] Bhandari M, Tornetta P, Sprague S, et al. Predictors of reoperation following operative management of fractures of the tibial shaft. J Orthop Trauma 2003;17:353-61.

[48] Burd T, Hughes M, Anglen J. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 2003;85B:700-5.

[49] Deguchi M, Rapoff AJ, Zdeblick TA. Posterolateral fusion for isthmic spondylolisthesis in adults: analysis of fusion rate and clinical results. J Spinal Disord 1998;11:459-64.

[50] Giannoudis PV, MacDonald DA, Matthews SJ, et al. Nonunion of the femoral diaphysis: the influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000;82B:655-8.

[51] Glassman SD, Rose SM, Dimar JR, et al. The effect of postoperative nonsteroidal antiinflammatory drug administration on spinal fusion. Spine 1998;23:834-8.

[52] Reuben SS, Ekman EF. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 2005;87A:536-42.

[53] Reuben SS, Ablett D, Kaye R. High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anaesth 2005;52:506-12.

[54] Mayer D. Sources of bias. In: Mayer D, editor. Essential evidence-based medicine. Cambridge (UK): Cambridge University Press; 2004. p. 74-86.

Clin Sports Med 25 (2006) 75-88

Arthritis Relief Now

Arthritis Relief Now

When you hear the word arthritis, images of painful hands and joints comes into play. Few people fully understand arthritis and this guide is dedicated to anyone suffering with this chronic condition and wants relief now.

Get My Free Ebook


Responses

  • milena
    What future implication of stress fractures?
    5 years ago

Post a comment